point break ride robot wave orthoped
initi zimmer biomet
pleas read import disclosur analyst certif appear appendix
differ analysi
rise robot
acquisit feed juggernaut quarter later becom organ
power effect
stryker comprehens orthoped portfolio posit win varieti market
consensu ep growth appear capit alloc leav room
neurotech spine
comprehens product portfolio abl compet current healthcar environ
manag know need turn ship around
zimmer biomet could reduc exposur orthoped long-term
strong ebitda margin compar peer lead outsiz free
regulatori challeng could requir invest forese futur
sustain gross margin pressur head
enter robot market inning
employe moral continu challeng cultur chang take longer expect
portfolio manag may help improv averag growth rate much
point break ride robot wave orthoped
initi zimmer biomet
initi larg cap orthoped launch two
compani buy pt zimmer biomet
neutral overal believ fundament driver orthoped procedur
remain steadi increas demograph increasingli older
popul world-wide increas incid obes combin
improv surgic technolog robot make joint
replac easier patient patient recov quicker procedur
variabl reduc demograph asid price headwind continu
lsd msd forese futur hospit push back
suppli cost robot earli stage adopt
orthoped survey hospit administr indic
pay check robot system orthoped view technolog
favor expect robot knee procedur ramp steadili
come year analysi broader sector survey work
compani initi includ
consist sale juggernaut yield steadi return ep
upsid initi buy pt collect across divis
shown abil grow organ revenu consist
multipl broader medic technolog market believ
diversifi revenu composit consist execut
combin lead posit orthoped robot
made name long-term one investor reli
encourag return time total return stryker
result compound-annual-growth-rate well ps even
stryker premium valuat expens respect
execut believ worth own month basi
initi buy pt
leader orthoped midst turnaround
challeng remain fore initi neutral current
midst turnaround new management helm qualiti
remedi effort one zbh manufactur facil
progress revenu guidanc equat xfx
view achiev remedi effort
manufactur facil may take longer anticip
interact fda continu requir intens focu
margin hamper sale momentum due dynam
multipl challeng could impact time management
expect two-year turnaround initi neutral
pleas read import disclosur analyst certif appear appendix
broad view joint reconstruct today
global orthoped market estim orthoworld
annual report compris joint reconstruct knee hip
extrem spine trauma arthroscopy/soft tissu orthobiolog
area hundr compani particip global
orthoped market size alon attract new entrant narrow
joint reconstruct global joint reconstruct market
estim broader orthoped market
domin four main player zimmer biomet neutral
smith nephew snn rate four main player account
global joint reconstruct market estim
global joint reconstruct market grew driven hsd growth
extrem matur lsd growth knee hip
said driver growth joint reconstruct remain favor
stabl demograph increas proport world-wide popul
requir new knee hip extrem continu grow offset
demograph growth continu price headwind primarili within
us market hospit payer seek lower price manufactur
price pressur expect remain constant forese futur
stem varieti factor includ rise overal cost healthcar
effort mitig cost increas lack profit margin
provid name health system hospit success outcom
replac remain one success procedur medicin
studi show knee hip implant last well year
effort allevi price headwind improv clinic outcom note
manufactur introduc complimentari technolog
patient-specif cut guid navig soft-tissu balanc among
other one may even argu introduct robot mani way
attempt stave price pressur offer capit compon
histor capital-less sale said earli clinic result
show reduct cost overal episod care also
improv clinic outcom enhanc precis due robot
look ahead believ winner joint reconstruct market
manufactur abl transvers clinic set inpati
outpati technolog offer improv clinic outcom
reduc overal cost episod care believ robot
technolog trend overtak larg four player market
result technolog advanc patient specif cut guid
navig soft-tissu balanc push improv qualiti
outcom interest payer provid reduc procedur
variat amongst surgeon combin effect effort result
lower cost health system specif post-op phase
joint reconstruct recoveri patient outcom improv
survey hospit exec support robot adopt base
administr expect growth robot procedur survey
hospit ceo cfo coo around countri understand
view robot orthoped overal believ administr
expect increas proport knee procedur done
robot favor continu system uptak major
respond robot system consist percentag
broader us market believ administr attitud indic
expect growth robot welcom technolog
help sale system would appear us administr
familiar robot technolog orthoped compani may
necessari need educ person cut check physician
interest histor dynam often slow sale
cycl larg capit equip hospit base survey respons
would appear may much issu seller larger
robot system larg joint orthoped survey support bullish view
continu growth robot system multipl year
robot scenario analysi mako adopt lead us believ
garner market knee growth multipl year base
case scenario conduct in-depth scenario analysi test bullish
view mako see whether current growth trajectori leav opportun
upsid number runway system sale could look like
multipl year analysi suggest key takeaway
instal base growth achiev
neutral analyst lavin like level still ampl runway
multipl year current sale trajectori
util skew higher base increas adopt
amongst smaller instal base continu accept
combin effect result doubl digit percentag growth
mako-bas knee procedur within syk knee
segment includ take busi away syk exist
knee sale clear state report
doubl digit knee growth quarterli basi base
analysi expect grow knee segment
industri top-line growth forecast period base
base case scenario even util bear case
scenario higher averag price pressur expect
syk knee segment grow overal
knee market may chang competit account buy less
mako unit today
glassdoor employe rate suggest protract turnaround employe
moral requir addit invest zimmer biomet corpor
cultur turn-around overnight expect zimmer biomet
signific amount work overal compani rate improv
compar zimmer biomet overal rate employe review site
glassdoor com note averag rate star scale
rate profil declin past two year
note recent rate appear hit low begun stabil
recent appoint ceo bryan hanson expect zimmer
biomet continu invest higher level order retain
employe fill open posit improv overal moral cultur
improv remain top prioriti management zimmer biomet rate
smith nephew depuy synth
maintain steadi rate base varieti
comp benefit career opportun
joint replac market well compani sell devic
industri domin zimmer biomet
depuy synth smith nephew four compani bring
global revenu gener knee hip replac
global knee market gener revenu
come us come ou zimmer
biomet held lead global posit market share
base revenu revenu follow
share revenu johnson johnson depuy synth
smith nephew round market share
revenu respect smaller compani
outsid made remaind market share
revenu
us market larg resembl global market term market share
zimmer biomet maintain domin posit
revenu follow revenu depuy
synth revenu smith nephew held slightli
smaller share us revenu smaller compani
made lower share smith nephew market share
revenu
market outsid us zimmer biomet largest vendor
market share revenu depuy synth
second largest player industri market share
revenu follow smith nephew share
revenu share revenu smaller
compani made market gener
global hip market gener revenu
come unit state come ou
global leader hip zimmer biomet global
market share global revenu depuy synth
smith nephew market share revenu
respect smaller compani
hip market made larger percentag market knee non-
compani take global market share
zimmer biomet held less domin posit domest take
us market revenu depuy synth held
larger market share domest global depuy
synth gener sale gener smith
nephew rel small us market share bring
us-bas revenu gener non-big vendor held
market share gener sale
market outsid us zimmer held largest share gener
market share revenu depuy synth held second largest
share revenu smith nephew
round market share revenu
respect compani outsid held
share market gener revenu
word growth driver
discuss orthoped begin without look view
public health challeng boon orthoped industri age
global popul candidli world get older isnt babi
boomer unit state post-war gener europ
world-wid trend across numer countri contin
peopl world-wid popul approxim
year older total popul segment
world-wid popul rose total go
subsequ year censu bureau predict
world popul year older said
popul peopl year older rise proport work age
peopl rise modestli peopl age remain
rel flat orthoped industri serv varieti segment
within popul mostli notabl tie older
musculoskelet care need greatest peopl age segment
popul believ favor tailwind last orthoped
potenti anoth year base demograph forecast
figur proport world-wide popul expect increas
increas incid obes
less public equal import obes impact
joint increas weight multipli effect joint strain extra
singl pound bodi weight four six pound pressur exert
knee joint increas biomechan load knee wear away
cartilag cushion result develop osteoarthr oa
ultim subsequ need joint replac rate obes
world-wide expect continu rise rapidli overal proport
countri outsid us expect remain us obes level
signific increas expect across europ asia incid
expect increas countri like franc uk
rate switzerland korea expect almost doubl
phenomenon limit adult either childhood obes expect
increas across globe similar rate combin increas
earlier incid obes caus higher level osteoarthr
provid tailwind broader orthoped sector bolster long-term
demograph trend joint replac need
figur expect increas obes amongst variou countri
organis econom co-oper develop
improv surgic technolog
knee replac surgeri one success procedur
medicin show revis rate due implant failur annual
revis rate follow year post-op singh et al arthriti research
hip replac procedur similar total knee replac
highli util procedur strong clinic result long-term meta-
analysi journal bone joint research show mortal rate
post surgic day follow hip
replac berstock et al bone joint research gain
util outcom surviv occur parallel
improv surgic technolog joint reconstruct view
anoth driver growth forese futur specif
obesityyearmexicounitedstatesenglandcanadaspainitalyfrancekoreaswitzerland
improv materi surfac technolog peri post-op
manag techniqu work togeth last year
extend implant wear improv function follow joint replac
look forward believ robot combin navig patient
specif bone tissu cut soft-tissu balanc increas
demand joint replac make procedur approach
palat eye patient robot
figur patient specif bone cut guid navig
larg joint orthoped consist price pressur
numer year larg driven constrain hospit profit
fierc competit amongst manufactur suppli cost largest
cost line hospit behind labor cost surpris
hospit look reduc price higher cost implant product
knee hip implant especi may product util
variat amongst surgeon staff given facil without differ
clinic outcom believ price pressur continu
forese futur due hospital/health system percept right wrong
lack innov product segment joint reconstruct note
manufactur reluctantli accept price headwind effort
mitig headwind note manufactur introduc
complimentari technolog patient-specif cut guid
navig soft-tissu balanc among other may even argu
introduct robot mani way attempt stave price
pressur offer capit compon histor
break implant subcategori bilater tradit
tka unicondylar see pronounc pressur tradit tka
unicondylar bilater like due larger volum tradit tka
rel procedur type easier gain leverag
common procedur contractu discuss similar dynam
occur hip wherebi coat stems/ceram stem seen highest
price pressur common procedur rel coat
stems/met head mobil bear hip notabl grown asp
much smaller proport tha procedur
rise robot
declin product cost per case manufactur
experienc past year believ natur find new
product solut could off-set price declin improv
surgic outcom order improv valu manufactur provid
manufactur attempt introduc technolog includ materi
scienc enhanc implant viviacit- zimmer
tissu balanc sensor comput assist surgic tool
individu product achiev modest penetr amongst
orthoped surgeon never becam standard care
introduct robot robot assist joint reconstruct take mani
featur softwar individu product may offer combin
form collect system significantli enhanc surgic experi
surgeon patient hospit alik addit believ robot
serv signific market tool physician hospit
differenti amongst competitor seen intuit
surgic commerci experi patient sought physician util
technolog believ similar dynam may occur robot joint
reconstruct patient view technolog clinic benefici
robot
clinic data limit point run multipl clinic trial
increas repositori clinic data respect tka
note earli data partial knee replac sinc first indic
robot encourag retrospect analysi commerci
insur claim show lower readmiss rate
figur retrospect analysi commerci claim mako pka
regardless clinic data patient market even confluenc
technolog enhanc believ robot garner signific
interest surgeon investor alik stryker result
strong driven strong uptak robot system procedur
growth implant usag collect result market knee growth
note though compani offer robot
product smith nephew zimmer biomet johnson johnson
recent acquisit orthotaxi enter robot joint
reconstruct market enter market futur
technolog differ system name cut mechan
presenc absenc haptic feedback requir lack-
thereof ct imag design pre-op intra-op
surgic plan overal premis view robot enhanc
precis accuraci implant fit algorithm base tissu
cut remov potenti variat human error
end compar robot system appendix dig deeper
robot proprietari survey hospit administr
feel pois speak purchas habit robot
director administr across countri hospit
size get read potenti ramp orthoped robot surgeri system
administr view robot larg joint reconstruct
survey focu orthoped surgeon respect view feel
administr perspect less explor equal
import purchas larg capit equip robot system
lavin grown tremend recent year look back mani
administr oppos technolog certain time isrg
commerci histori least argu cost per case
expens particularli gener surgeri procedur rel
reimburs payer believ view larg dissip
clinic data econom studi look entir episod care
clinician interest isrg result born well
look ahead could potenti prove multi-year growth driver
orthoped devic manufactur want ensur administr
on-board robot joint reconstruct
question focus whether hospit system current
use plan purchas robot system util plan
util system well vendor prefer robot impact
vendor prefer note sampl size came lower
expect still believ respons enough provid lead
insight overal administr percept sampl size
potenti hospit administr reach
survey demograph show broad cross section american
survey includ broad divers cross-sect hospit us
mix commun teach hospit academ medic center
figur survey respond locat hospit type
survey respond composit also includ variat amongst
number bed given facil number oper room
believ larger facil like first purchas robot
system note survey screen smaller hospit
mani could potenti becom custom time
figur survey respond bed size number oper room
hospit survey part larger health system
encompass hospit cumul self-report annual revenu
averag annual number surgeri perform hospit
survey per year rang averag
number orthoped surgeri perform hospit survey
overal sentiment surgic volum appear posit
overal within knee reconstruct
overal sentiment surgic volum appear posit
respond expect surgic volum modestli
next month expect volum flat expect
signific increas volum next month growth
attribut new physician addit local demograph growth
respond cite volum flat note shift primari
driver orthoped shift procedur prevail view mani
figur overal surgic procedur expect next month
ask survey respond estim whether expect growth
subsector next month notabl increas expect
knee spine expect larg flat
figur expect surgic growth sub-seg
knee growth
respond
spine expect
remain
amongst
ask respond market share primari implant vendor
joint reconstruct note came away leader
amongst survey respond sampl size small use
baromet market share said respond expect
share remain rel constant next month
figur anticip chang use joint reconstruct product next month among
subsequ question ask respond plan
renegoti suppli contract primari implant vendor
respond answer say expect renegoti
next month averag anticip price reduct rang
 note high rel price pressur
fallen orthoped ultim would expect contract price fall
lsd msd rang consist histor pattern even
administr hope get
expect shift robot come year
hospit execut survey site own robot system mako
unit navio unit smith nephew proport
robot system instal rel without robot unit consist
survey overal proport seen us hospit environ
today ask respond specif system chosen owner
robot system cite two reason purchas total knee applic
provid prefer
addit hospit site system satisfied/veri
satisfi robot system expect knee volum
increas result own robot system proport knee
procedur perform robot rel overal knee procedur
volum vari among site robot system though
site without system ask whether hospit
consid purchas system next month singl
respond note intent purchas next month
ask lack surgeon interest common reason cite
amongst respond felt next question tell
market head time
ask survey respond look futur tell us
proport total knee replac procedur anticip
perform robot next month
figur expect percentag knee replac perform robot given facil
next month survey respond
expect robot procedur compris
overal knee procedur may prove
aggress suggest administr
recept robot technolog orthoped
overal believ expect increas proport knee
procedur done robot favor continu system uptak
mani respond robot system time believ
administr attitud indic expect growth
robot welcom technolog help sale
system would appear us administr familiar robot
technolog orthoped compani may necessarili need
educ person cut check physician interest
histor often slow sale cycl larg capit
equip base survey respons would appear may
much issu seller larger robot system larg joint
ask respond write view benefit
challeng robot system orthoped respond answer
provid
figur benefits/challeng robot system orthoped administr perspect
would appear us administr understand much intend
benefit robot system larg joint reconstruct base answer
note hurdl broader adopt like remain up-front
cost common reason cite adopt
agreement system major surgeon prefer indic
monthsbenefitschallengesaccuracycost lo etcconvinc surgeon use greater surgeon accuraci precis patient comfort surgeri increas navigationcas time quicker result less complicationsagre right platform amongst robot system view robot cut edgeremain currentstandardizationmarket joint replac center attract new surgeon center
ep upsid initi buy pt
broad-bas leader medic technolog oper
varieti segment orthopaed medsurg neurotechnolog
spine collect across divis shown abil
grow organ revenu consist multipl broader medic
technolog market believ diversifi revenu composit
consist execut combin lead posit
orthoped robot made name long-term one
investor reli encourag return time total
return result compound-annual-growth-rate well ps
even premium valuat expens respect
execut believ worth own month basi
initi buy pt
consist top-lin execut follow grown
organ revenue straight quarter consist top-lin
execut buoy divers portfolio mix oper
multipl high growth segment med-tech note initi
growth across entir product portfolio well balanc
support tuck-in acquisit continu add
product mix strateg tuck-in leverag syk exist sale
channel open new market opportun area
lead orthoped robot mako instal ww
believ pull away pack lead outsiz knee
implant growth multipl quarter util grow rapidli
mako scenario analysi suggest mako runway
util increas hospit ceo survey suggest admin
comfort robot adopt today rel histor
focu ep growth om leverag management commit
om expans annual syk ctg program
result ep growth syk floor set late
valuat stryker rate buy pt base
month adjust ep risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
compani descript broad-bas leader medic technolog
design develop manufactur distribut product servic
orthopaed medic surgic neurotechnolog spine help
improv patient hospit outcom
stryker capit strategi includ growth dividend payment share
buyback order long-term focus organ growth
high-end med-tech peer intern cost optim drive
oper margin expans annual next year minimum
invest thesi collect across divis shown abil
grow organ revenu consist multipl broader medic technolog
market believ diversifi revenu composit consist execut
combin lead posit orthoped robot made
name long-term one investor reli encourag return
time total return result compound-annual-growth-rate well
 ps even premium valuat expens
respect execut believ worth own month basi
initi buy pt
guidanc organ sale growth adjust ep
driver growth mako unit sale pull-through
implant neurotechnolog stroke sage return growth endoscopi
product medic product
omx expans plan transform growth ctg syk long-term
strategi improv cost structur minim impact growth
management guid om expans year year period
invest thesi view
broad-bas leader medic technolog oper varieti segment orthopaed medsurg neurotechnolog spine
collect across divis shown abil grow organ revenu consist multipl broader medic technolog market
believ diversifi revenu composit consist execut combin lead posit orthoped robot made
name long-term one investor reli encourag return time total return result compound-annual-growth-rate
well ps even premium valuat expens respect execut believ worth own
month basi initi buy pt
expand thesi believ lead posit orthoped robot continu allow pull away pack
recent indic expans mako robot system cement-less knee clinic data bolster mako growth implant pull-
mako specific-account result knee growth overal market level indic incom competitor robot lot
overcom catch domin posit base in-depth analysi compar mako growth trajectori
neutral analyst lavin da vinci system believ signific room growth number instal unit procedur per instal
unit forecast instal base smaller due smaller potenti custom base da vinci management cite potenti us
hospit potenti orthoped practic believ mako procedur per unit exceed da vinci system lead continu
market share gain knee also believ mako expand custom base give signific in-road yet-to-be-announc area
robot spine soft-tissu robot decid expand mako beyond orthoped reconstruct
combin dynam believ acquisit strategi result higher revenu growth complimentari area beyond orthoped
build exist sale channel acquisit strategi result higher growth diversifi revenu base away
orthoped allow compani particip key growth market name stroke endoscopi pre-op patient prepar
establish consist top-lin execut organ inorgan sourc compani turn focu improv ep leverag
past month
oper margin expans strategi place name transform growth ctg target margin
improv annual next year note exclus dilut natur acquisit impact margin expans
along one-tim impact hurrican ultim margin improv allow drive ep growth management set
minimum annual said averag ep growth sinc announc floor believ street estim may
underestim abil gain leverag bottom-lin sum take bullish view abil execut top
bottom line initi buy pt
compani size abil consist grow organ revenu high end med-tech impress also speak
cultur durabl investor come expect kalamazoo michigan base compani even tough comp management began
year guid organ revenu growth sinc rais guidanc twice organ growth expect
revenu base organ revenu note growth balanc across three busi unit show
area strength medic endoscopi neurotech market knee growth driven mako pull impact
tougher comp organ growth year year comp view beatabl given organ growth
alreadi achiev
rel overal med-tech market shown abil consist grow organ revenu beyond overal market driven
combin variou higher growth busi pair matur complimentari product offer said forward revenu
compound-annual-growth-rate in-lin slightli large-cap peer note highest among larg cap orthoped competitor note
divers revenu base orthoped peer help support higher revenu growth
figur growth rel overal medic technolog left revenu compound-annual-growth-rate rel peer right
relat sale growth think durabl reflect
consecut quarter grown organ sale grow sale
top strong growth prior year year year year would say
someth demonstr consist kevin lobo earn call
acquisit feed juggernaut quarter later becom organ
acquir variou med-tech compani either bolster exist sector current compet vexim spine provid
product adjac sector may allow compani enter new market segment futur believ follow
strategi consist integr compani sale forc rapidli larger organ recent acquisit novadaq entellu
physio-control exampl view upon acquisit novadaq grow sale y/i recent quarter prior acquisit
note novadaq expect grow high doubl digit entellu grew revenu y/i quarter acquisit
larg due spirox expect grow y/i lastli physio-control shown strong doubl digit growth
follow acquisit help lift medic result
importantli see acquisit strategi diversif strategi away orthoped acquisit physio
method entryway new segment med-tech compani hasnt histor exampl acquir
novadaq bolster endoscopi offer also enter surgic plastic surgeri segment novadaq dermacel product
novadaq sell dermacel plastic surgeon believ dermacel stand-alon product make signific inroad surgic
plastic surgeri give sale channel layer legaci product time view real valu
dermacel compon novadaq acquisit time believ acquisit similar novadaq support new growth opportun
said afraid make larger bet mako time acquisit appear specul costli ttm
sale today momentum see mako vindic previou specul everi large-cap orthoped compani sinc
enter orthoped robot market plan enter believ stryker head start mako allow compani pull away pack
metric management provid show strong momentum
look back acquisit histori today note paid certain asset also purchas numer compani
fairli reason price orthovita ttm sale berchtold ttm sale physio-control ttm sale total paid
averag ttm sale acquisit publicli disclos revenu btig intern med-tech acquisit tracker
note acquisit averag ttm sale
power effect
acquir mako surgic pay ttm sale acquisit time appear expens specul
orthoped robot pervas technolog today persist develop technolog today mako momentum
part reason share appreci recent disclosur management show power mako broader knee implant
sale name mako unit sale competit knee vendor account account mako system total knee
applic see knee implant sale account without
follow broad launch total knee applic mako gain fda clearanc use cementless product offer
mako total knee applic given total knee perform cementless believ indic could
support robust mako growth beyond exist custom base addit publish conduct numer clinic
trial bolster support use mako amongst surgeon
data say thu far limit clinic research use robot tka compar non-robot tka although
cadaver studi said run multipl clinic trial increas repositori clinic data respect tka
expect later data partial knee replac encourag retrospect analysi commerci insur claim
show lower readmiss rate day robot partial knee replac addit note follow studi current on-go
figur retrospect analysi commerci claim mako pka left on-go studi right
time believ could util mako area outsid orthoped reconstruct name spine soft-tissu robot spine
franchis would surpris us design current design compon mako serv burgeon spinal robot market
addit presenc oper room endoscopi instrument could possibl also see move
soft tissu robot mako
statusstudi titlestudi sizeprimari complet dateactiveclin econom comparison robot assist versu manual knee trial evalu compar perform use mako robot assist mako robot system compar convent tka mechan recruitingmako-uni-kne outcom robot assist medial partial knee outcom knee lengthmetricreadmiss rateallow per readmiss readmiss rateallow per readmiss day
power effect cont
conduct in-depth scenario analysi test bullish view mako see whether current growth trajectori leav opportun
upsid number runway system sale could look like multipl year
forecast potenti mako system revolv around three assumpt proxi mako forecast broadli compar
commerci path isrg da vinci system found util per procedur track fairli close isrg
growth mako instal base base system sale report unit forecast bull/base/bear case take account
older system retir instal base base histor unit volum sale
growth mako util measur annual procedur per unit compar procedur volum use
roll averag forecast futur util segment isrg growth stage rate seen quarter lead
mako quarter util quarter follow period flat declin util quarter
period stabl util growth bull util case mako util growth rate quarter
temper next quarter lower rate similar path follow base case util rate
initi rate bear case util rate throughout instal base util forecast combin get quarterli
procedur forecast approxim annual mako-bas procedur volum
cost per implant final assumpt price forecast appli volum forecast get annual mako-bas revenu
forecast blend asp base averag construct price tka pka tha appli price pressur annual
initi per-procedur price baselin forecast go price forecast high bull scenario implant price
stay flat bull case price declin base case declin bear case declin bear case
declin appli futur year baselin declin
figur histor project unit instal base left util right
mako instl base banddv sold qmako sold qdv inst baseu mako instl baseu mako instl base per dvproject follow per mako
power effect cont
in-depth analysi suggest key takeaway
instal base growth achiev like level still ampl runway multipl year current sale trajectori
lower potenti hospit base combin fewer indic compar da vinci system lead us forecast lower year
instal base mako system
mako system abl gain sizabl instal base estim us hospit
potenti believ may challeng competit system enter
market forecast base case mako system end
util skew higher base increas adopt amongst smaller instal base continu accept robot util
base case forecast annual procedur per unit increas procedures/year procedures/year rang
procedures/year procedures/year bear bull case broadli higher current da vinci rate due exclus
period declin da vinci util
higher skew da vinci util repres confid adopt robot surgic system increas in-
hospit share robot procedur take combin concentr instal base support continu orthoped surgeon
combin effect result doubl digit percentag growth mako-bas knee procedur industri top-line growth
compani knee segment forecast period
combin forecast project mako-bas procedur forecast base case gener revenu equat
top-line growth knee segment forecast assum mako system continu instal
competit account assum revenu growth knee cannib exist implant sale
implant perform mako system leav top-line growth knee segment excess industri growth
stryker comprehens orthoped portfolio posit win varieti market
highlight key product within orthoped product portfolio believ due expans product portfolio address
broad rang custom need support larger contract effort within health system gpo idn product either market leader
within respect categori near market leader
triathlon triathlon tritanium total knee system knee product shown survivorship year respect
mistri et al epinett et al product design incorpor varieti option includ cr cs ps core triathlon triathlon tritanium
address grow usag cementless knee reconstruct knee unit volum addit knee implant mako
total ankl total ankl modular compon allow patient match configur singl surgic techniqu long-term
clinic studi shown survivorship year respect karantana et al believ total ankl offer foot ankl
surgeon uniqu total ankl replac option fast grow still small total ankl replac market
vitoss vitoss highli porou beta-tricalcium phosphat strong clinic data support fusion import point vitoss synthet bone
graft substitut player spine synthet biolog believ market migrat away higher price option stem cell
bone morphogen protein synthet biolog may abl fill market demand higher price option consist reproduc outcom
believ product portfolio outsid orthoped equal compel revenu non-orthoped relat combin
instrument endoscop equip bed stretcher defibril patient safeti spinal implant neurovascular product mani product
offer note within medsurg segment capit intens busi result lumpi sale quarter quarter becom
less tie capit cycl dispos product compon convers recur dispos product impact
sell day variat quarter quarter capit compon medsurg busi tie sell day swing custom may purchas stryker
capit equip regardless sell day
collect broad portfolio product capit dispos serv varieti custom need also well posit bundl across
variou specialti particularli cost-consci consolid healthcar macro environ believ health system gpo idn
prefer vendor offer price discount scale exchang larger share larg capit contract collect portfolio result well
balanc growth across varieti subseg weve analyz growth import compani overal growth note isnt
singl subseg depend achiev overal compani growth
figur stryker quarterli growth analysi segment
transform growth ctg long-term strategi improv cost structur minim impact growth introduc
late program intend remov increas structur cost associ growth allow compani reinvest save back
top-lin growth management guid result ctg program initi result oper margin expans
year year period name program includ product line ration indirect procedur optim singl global enterpris resourc
plan system share servic transform manufactur site consolid
investor expect result program support oper margin note oper margin see much lift
larg due dilut acquisit novadaq impact hurrican account impact would result
improv oper margin
note though compar trend om held fairli steadi much earli yet om expand
model om lift higher beyond believ could opportun gm line management note biggest
opportun ctg program cog line product ration
figur gm om histor project left large-cap med-tech compar om right
rel peer ep compound-annual-growth-rate appear lower end larg cap med-tech analyst day management laid plan grow ep
minimum five-year horizon sinc plan laid set floor note grown ep consist
level averag y/i adjust ep growth ytd model forward annual basi believ opportun
may exist leverag specif driven ctg program opportun tax rate improv bit surpris given strength
ytd perform street model forward ep compound-annual-growth-rate even analyst conservat keep
ep estim measur exceed floor bp sinc announc long-term minimum
capit alloc leav room
alway priorit drive sale growth innov dividend share repurchas respect investor seen
acquisit sinc said still abl deploy dividend purchas back share note
remain author share repurchas program exit lever net debt/ adj ebitda current model
leverag ratio remain declin time believ base expect leverag ratio ampl capac take
either addit debt necessari continu use cash fund modest tuck-in acquisit continu pay dividend purchas share off-set
acquisit proceed expect
paid april midway recal product due warn letter sent fda
regard bacteria contamin sage product ultim issu remedi recal stunt sage expect double-
digit growth overal growth highlight one challeng acquir numer compani sometim acquisit may proceed
expect fortun tuck-in strategi limit impact singl acquisit compani whole none-the-less
challeng impact share neg may occur futur acquisit
acquisit also limit impact om expans
management guid om expans next year result impact numer factor name hurrican
puerto rico troubl novadaq acquisit remov item oper margin would in-lin
management plan unfortun investor remov one-tim item novadaq acquisit critic compon stryker
growth strategi believ investor account dilut associ acquisit particularli margin expect acquir
addit asset may dilut impact om expans particularli growth orient compani acquir
increas competit robot
mako clear lead joint reconstruct robot smith nephew navio zimmer biomet rosa robot system either current
compet mako futur compet mani account surgeon addit johnson johnson acquisit orthotaxi
provid competit robot option come market futur specif technic advantag trade-off
system highlight robot section way look market though new entrant enter challeng
share reconstruct robot market addit would surpris robot system market today move joint
reconstruct may current oper joint recon space name globu medic neutral excelsiusgp system
softer market specif segment
oper varieti market includ higher growth area orthoped robot neurovascular grow well
matur medic technolog market spine joint reconstruct grow lsd collect posit
diversifi revenu base across multipl market one singl market matur slow other may abl off-set soft
higher growth said slowdown specif market drag growth spine market stand us risk
saw lsd declin global spine market weak topic concern investor omiss
call certain product spine categori saw hsd ldd price pressur indic could face pressur select market would
constrain revenu growth note spine busi bounc back nice constant currenc growth
current trade ntm price-to-earnings median ntm price-to-earnings rel current trade ps ntm
price-to-earnings median rel healthcar equip servic composit current trade composit
ntm price-to-earnings compar ntm median rel ntm price-to-earnings
stryker rate buy pt base month adjust ep believ premium warrant share given
consist top-lin execut higher ep growth expect risk relat rate pt includ acquisit proceed expect
acquisit limit om growth increas competit robot softer market specif segment
price-to-earnings rel price-to-earnings rel hcntm laboratoriesabtneutr inc baxnot dickinsonbdxnot scientificbsxbuy lifesciencesewneutr nephew adrsnnnot factset data btig research estim ex-amortcompanytickerr ptpricemarket cap
trade analysi trade event
primarili trade nyse compani adv share dollar valu adv share
dollar valu
quarterli earn quarterli earn biggest singl indic success quarter provid detail commerci
progress trend compani profit believ key metric revenu growth overal segment organ revenu growth
adjust gross margin adjust ebitda adjust ep
acquisit net acquir numer medic technolog compani acquisit histori figur mani
acquisit tuck-in exist busi segment consist strategi smaller tuck-in may move
share may time time make larger acquisit trade event investor
broad-bas leader medic technolog design develop manufactur distribut medic technolog product servic
orthopaed medic surgic neurotechnolog spine help improv patient hospit outcom incorpor michigan
origin found dr homer today oper countri employe global
stryker revenu categor report segment orthopaed medic surgic neurotechnolog spine revenu
broken report segment subseg includ within orthopaed knee hip trauma extrem within
medic surgic instrument endoscopi medic sustain within neurotechnolog spine neurotechnolog spine
figur report structur left compani strategi right
stryker orthopaed segment repres revenu revenu segment compos knee hip trauma
 extrem sub-seg geograph perspect revenu gener us segment
revenu gener us
knee sub-seg compris portfolio knee joint replac product sale group risen past two year
segment made orthopaed sale gener estimate sale us
hip sub-seg compris hip joint replac product sale grown past two year
segment made orthopaed sale gener estimate revenu us
trauma extrem sub-seg compris broad array rod plate screw nail trauma remedi alongsid
extrem fixat portfolio sale grown segment made orthopaed sale
gener estimate sale us
sub-seg compris variou non-joint non-trauma product includ mako robot assist surgeri system
fastest grow segment orthopaed increas revenu segment repres
orthopaed sale estimate come us
figur orthopaed constant currenc revenu volum price growth
stryker medsurg segment repres revenu revenu segment compos instrument endoscopi
medic sustain sub-seg geograph revenu came within us respect
instrument sub-seg hold portfolio orthopaed saw drill accessori among product sale grown
past two year rise sale divis made larger medsurg segment
gener estimate sale us
endoscopi sub-seg contain compani portfolio surgic visual product hous recent acquir novadaq technolog
platform sale grown past two year endoscopi made medsurg
segment sale gener estimate sale us
medic sub-seg contain collect hospit product report segment physio-control acquisit
sale grown divis made medsurg sale gener estimate
sale us
sustain sub-seg provid patient care financi environment sustain solut sale grown past two year
smallest sub-seg medsurg sustain repres sale segment
major estim come us
figur medsurg constant currenc revenu volum price growth
neurotech spine
stryker neurotech spine divis hous togeth compani third segment repres compani revenu
revenu geograph revenu revenu gener us
stryker neurotechnolog sub-seg contain compani cranial neurovascular group cranial group hold compani cranial
surgeri product neurovascular group hold compani stroke care product sale grown past two year
sub-seg made segment sale gener estimate sale us
stryker spine sub-seg contain compani spinal fixat product sale grown last two year
sub-seg made segment sale gener estimate sale us
figur neurotech spine constant currenc revenu volum price growth
kevin lobo chairman ceo mr lobo ceo sinc octob chairman board sinc juli previous
group presid orthopaed join prior join mr lobo held role johnson johnson rhone-poulenc mr
lobo addit serv board director advanc medic technolog associ advam busi
leader michigan receiv bachelor mcgill univers univers toronto rotman school manag
glenn boehnlein cfo mr boehnlein join vice-president cfo sinc april recent group cfo
medsurg neurotechnolog join mr boehnlein cfo success tv arthur andersen receiv bachelor
master degre account mississippi state univers
timothi scannel presid mr scannel presid effect august previous group presid
medsurg neurotechnolog sinc januari mr scannel join serv leadership role endoscopi
spine medsurg divis addit mr scannel serv board director insulet corpor receiv bachelor
univers notr dame
katherin owen vice presid strategi ir ms owen join current role februari prior join ms
owen held research role merril lynch cowen co ms owen receiv bachelor econom univers massachusett
amherst boston colleg
incom etot y/i sale technolog special oper incom incom tax expens net incom share net incom share gross oper expens btig research estim compani report
revenu y/i q/q mixdomest btig research estim compani report
leader orthoped midst turnaround
challeng remain fore initi neutral
zimmer biomet diversifi medic technolog compani
design manufactur commerci broad rang
musculoskelet product leadership posit varieti area
current midst turnaround new management helm
qualiti remedi effort one zbh manufactur facil
progress revenu guidanc equat xfx
view achiev remedi effort manufactur facil
may take longer anticip interact fda continu
requir intens focu qualiti improv delay product
gain depress gross margin hamper sale momentum due
dynam multipl challeng could impact time
management expect two-year turnaround initi neutral
guidanc appear achiev valuat attract
result xfx growth xfx turnaround
stori appear take shape pipelin new product
yet releas robot system joint reconstruct
limit launch help improv overal revenu
growth guidanc appropri conserv valuat
ntm price-to-earnings attract
management unabl provid timelin qualiti remedi
suppli improv recent call view
management commentari assuag concern around on-go issu
hamper upsid growth leav us unsur
issu ultim rear-view mirror management
see issu prevent achiev
guidanc resourc continu divert support
ultim expect share remain rang bound
turnaround play make progress right ship
gener sizabl would becom construct
near-term risk abat growth level pick higher rate
valuat zimmer biomet rate neutral risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
